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Background: The clinical significance of circulating autoantibodies in idiopathic pulmonary
fibrosis is unclear. The objective of this study was to determine the frequency and clinical
significance of circulating autoantibodies in idiopathic pulmonary fibrosis.
Methods: Wemeasured an extensive panel of autoantibodies (including rheumatoid factor, anti-
cyclic citrullinated peptide, and anti-nuclear antibodies by immunofluorescence) associated
with connective tissue disease or vasculitis in a cohort of well-characterized patients with idio-
pathic pulmonary fibrosis (nZ 67). The prevalence of circulating autoantibodies was compared
between idiopathic pulmonary fibrosis patients and healthy controls (nZ 52). We compared the
clinical characteristics of patientswith andwithout circulating autoantibodies, and analyzed the
relationship between autoantibody positivity and transplant-free survival time.476 5897; fax: þ1 415 476 5712.
u (J.S. Lee).
to this manuscript.
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250 J.S. Lee et al.Results: Positive autoantibodies were found in 22% of patients with IPF and 21% of healthy
controls. There were no differences in the types of autoantibodies found between patients with
idiopathic pulmonary fibrosis and healthy controls. Among patients with idiopathic pulmonary
fibrosis, there were no significant differences in clinical characteristics between those with
and without circulating autoantibodies. The presence of circulating autoantibodies was associ-
ated with longer transplant-free survival time on adjusted analysis, however the significance
varied depending on which statistical model was used (HR 0.22e0.47, p value 0.02e0.17).
Conclusions: The frequency of circulating autoantibodies in patients with idiopathic pulmonary
fibrosis is no different compared to healthy controls, but may be associated with longer survival.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung
disease of unknown etiology characterized by usual inter-
stitial pneumonia (UIP) pattern on histopathology or radi-
ology.1 Central to the diagnosis of IPF is the exclusion of
a defined connective tissue disorder (CTD), as a UIP histo-
pathologic and radiologic pattern can be seen in patients
with CTD, in particular among those with rheumatoid
arthritis and scleroderma.2e6
Published guidelines suggest that all patients with
suspected IPF be screened with rheumatoid factor (RF),
anti-cyclic citrullinated peptide (CCP), and anti-nuclear
antibody (ANA) testing, even in the absence of CTD
symptoms. Further, it is recommended that those
patients with positive screening results be carefully
evaluated for an occult CTD, often in consultation with
a rheumatologist.1,7 Importantly, circulating autoanti-
bodies have been described in patients with IPF who have
no evidence of a defined CTD.2,8e10 However, the clinical
relevance of these circulating autoantibodies remains
unknown.
In this study, we investigated the frequency and clinical
significance of commonly measured circulating autoanti-
bodies in a well-characterized cohort of patients with IPF.
We sought to determine if the frequency and type of
circulating autoantibodies in patients with IPF differed
from two control populations, healthy, age-similar controls
and patients with undifferentiated connective tissue
disease (UCTD). In addition, we examined whether patients
with IPF and circulating autoantibodies comprised a distinct
clinical phenotype and whether the presence of circulating
autoantibodies in IPF influenced survival.Materials and methods
Study population
Patients with IPF seen between October 2005 and May
2010 were identified from an ongoing cohort study of
interstitial lung disease (ILD) at the University of Cal-
ifornia San Francisco (UCSF). Signs and symptoms of CTD
were systematically and prospectively collected on all
patients. This Institutional Review Board-approved cohort
included informed consent for the use of clinical data andbanked serum for future studies. Patients were included
in the current study if they had a diagnosis of IPF based
on the previous guidelines and had banked serum
available.11
The primary control population was healthy volun-
teers, ages 50e80 years old. We also identified all
patients in the UCSF database who had banked serum
available and a diagnosis of undifferentiated connective
tissue disease-associated (UCTD) ILD. Patients were
given a multidisciplinary diagnosis of UCTD-ILD if they
have at least one clinical manifestation suggestive of
a CTD (e.g. Raynaud’s, arthralgias, dry eyes and mouth),
at least one positive serology, and absence of sufficient
American College of Rheumatology criteria for a defined
CTD.12Radiological evaluation
Available chest high-resolution computed tomography
(HRCT) scans for patients with IPF were re-evaluated by
a thoracic radiologist blinded to the clinical course and
autoantibody status of all patients. UIP pattern (yes or no)
was identified based on current criteria.1Autoantibody profile
An extensive autoantibody evaluation was performed on
banked serum from all patients. The laboratory was blinded
to the diagnosis and other clinical features of all patients.
ANA by immunofluorescence assay (IFA) and RF by nephe-
lometry were performed by the UCSF Clinical Laboratory
according to standard protocols. Additional autoantibody
testing was performed using the BioPlex 2200 System (Bio-
Rad Laboratories, Hercules, CA). This system is an FDA-
cleared fully-automated random-access analyzer, which
employs multiplexed fluoromagnetic bead technology to
simultaneously perform measurements of multiple auto-
antibodies in a single sample.13 The following circulating
autoantibodies were tested using the BioPlex system: anti-
cyclic citrullinated peptides (CCP), Smith (Sm), ribonu-
cleoprotein (RNP), SmRNP, Scl-70, Jo-1, anti-Ro (SS-A),
anti-La (SS-B), double stranded deoxyribonucleic acid
(dsDNA), chromatin, ribosomal P, centromere B, proteinase
3 (PR3), myeloperoxidase (MPO), and glomerular basement
membrane (GBM).
Table 1 Baseline demographics.a
IPF
(n Z 67)
UCTD-ILD
(n Z 22)
p value
Age, years 69 (8) 60 (11) 0.04
Female gender 16 (24%) 18 (82%) <0.01
Ever smoker 50 (75%) 9 (41%) 0.09
Dyspnea scoreb 9.4 (6.1) 10.1 (5.9) 0.57
Joint pain or
stiffness
27 (43%) 9 (41%) 0.46
Dry eyes or mouth 14 (23%) 6 (27%) 0.36
Raynaud’s 4 (7%) 3 (14%) 0.15
Reflux symptoms 29 (44%) 9 (41%) 0.31
Current prednisone
therapy
18 (29%) 16 (73%) <0.01
Current azathioprine
therapy
6 (10%) 0 (0%) 0.15
Long-term oxygen
therapy
12 (18%) 4 (18%) 0.64
Forced vital capacity,
% predicted
68 (17) 66 (17) 1.00
Diffusing capacity for
carbon monoxide,
45 (18) 46 (14) 0.83
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Patients were categorized as autoantibody positive if they
had one or more circulating autoantibody levels above the
established reference values, except for ANA and RF. An
ANA titer of 1:320 and a RF value of 60 IU/ml were
considered positive.14
Intergroup comparisons were performed using an
unpaired t-test, Chi-squared test, or Fisher’s Exact test, as
appropriate. Transplant-free survival time was defined as
time from serum collection to transplant, death or
censoring as determined by review of clinic records and the
Social Security Death Index. KaplaneMeier survival esti-
mate curves were generated and compared using the log-
rank test. Two adjusted Cox regression approaches were
used to determine the predictive value of autoantibody
status on transplant-free survival in IPF. The first model
adjusted for covariates that were considered a priori by the
investigators to be important potential confounders of the
relationship between autoantibody positivity and survival
(i.e. age, gender, and smoking status). The second model
adjusted for covariates that were found to have a p value
<0.15 on unadjusted analysis. All statistical analyses were
performed using STATA version 11 (College Station, TX).
Significance was defined as a p-value of <0.05.% predicted
Definite UIP pattern
on HRCT(1)c
27 (52%) 5 (24%) 0.13
Surgical lung biopsy
performed
30 (45%) 9 (41%) 0.71
IPF e idiopathic pulmonary fibrosis; UCTD e undifferentiated
connective tissue disease; ILD e interstitial lung disease; UIP e
usual interstitial pneumonia; HRCT e high-resolution computed
tomography.
a Data are presented as n (%) or mean (SD).
b Score from Clinical-Radiographic-Physiologic (CRP) Dyspnea
Score.23
c HRCT available for re-review in 52 patients.Results
Patient characteristics
Sixty-seven patients with IPF and banked serum were
identified from the longitudinal cohort. There was no
significant difference in baseline characteristics or survival
time between IPF patients with and without available
serum (Supplementary Table 1, Supplementary Fig. 1). The
vast majority of patients had their blood drawn at the time
of their initial clinic visit (median time between initial
clinic visit and blood draw 0 days, inter-quartile range 0,
0 days). Only four patients had their blood drawn more than
6 months from their initial clinic visit.
Patients with IPF were predominantly male with a mean
age of 69 (Table 1). Seventy-five percent were current or
former smokers. The mean forced vital capacity (FVC) was
68% predicted and the mean diffusion capacity for carbon
monoxide (DLCO) was 45% predicted. Eighteen percent re-
ported long-term oxygen therapy.
The healthy control population included 52 people (26
women and 26 men), ages 50e80 years old. The UCTD-ILD
cohort included 22 patients (Table 1, see below for further
description). Some of these patients have been previously
reported.12
Frequency of circulating autoantibodies
One or more positive circulating autoantibodies were
detected in 22% patients with IPF and 21% of healthy
controls (p Z 0.73, Fig. 1).
The majority of IPF patients and healthy controls had
a negative ANA by IFA (73% in both groups, pZ 0.99, Table
2). Low-level ANA titer positivity (1:40 and <1:320) waspresent in 25% of patients with IPF and 27% of healthy
controls (p Z 0.84). Only one IPF patient had a high ANA
titer. This was an 81 year-old man with no rheumatologic
signs or symptoms and an ANA titer of 1:640 (mixed
speckled and diffuse pattern). Overall, the ANA patterns in
the IPF patients and healthy controls with detectable ANA
titers were similar; only one IPF patient had a nucleolar
staining pattern. This was a 50 year-old woman with no
rheumatologic signs or symptoms and an ANA titer of 1:40.
The rheumatoid factor was positive in 6% of patients
with IPF and none of the healthy controls (pZ 0.09). There
was no difference in CCP antibody positivity between
patients with IPF and healthy controls (p Z 0.86). There
were no significant differences between IPF patients and
healthy controls in the frequency of any of the other indi-
vidual autoantibodies.
Circulating autoantibodies and clinical phenotype
in IPF
There were no significant differences in baseline demo-
graphics, pulmonary function test values, or the presence
Figure 1 The frequency of circulating autoantibody posi-
tivity in healthy controls (white bars) compared to idiopathic
pulmonary fibrosis (IPF, black bars). There were no significant
differences in frequency of autoantibodies between healthy
controls and IPF. “Other” includes double stranded deoxy-
ribonucleic acid (dsDNA), chromatin, ribosomal P, anti-Ro (SS-
A), anti-La (SS-B), centromere B, Smith (Sm), ribonucleopro-
tein (RNP), SmRNP, Scl-70, Jo-1, proteinase 3 (PR3), myelo-
peroxidase (MPO) and glomerular basement membrane (GBM).
Abbreviations: ANA e anti-nuclear antibody, RF e rheumatoid
factor, CCP e cyclic citrullinated peptide.
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with and without circulating autoantibodies (Table 3).
Similarly, there were no significant differences in CTD
symptoms or the use of immunosuppressive medications
(i.e. prednisone and azathioprine), between these two
groups. Upon re-review of the IPF autoantibody positive
subgroup, only one IPF patient, a 75 year-old man with
symptoms of gastroesophageal reflux and arthralgias, was
found to have an associated circulating antibody detected
on the analysis of banked serum e an isolated positive RNP.
This patient had definite UIP pattern on HRCT and serologic
evaluation at the time of diagnosis, including ANA, RF, SSA,
SSB, aldolase, and Scl70, were negative. Follow-up on this
patient could not be performed because he had died by the
time this information was available.
Comparison of IPF autoantibody positive patients to
UCTD-ILD patients
Compared to the IPF autoantibody positive group (nZ 15),
the UCTD-ILD patients (n Z 22) were younger (60 vs. 67
years, p Z 0.04), more likely to be female (82% vs. 20%,
p < 0.01), and less likely to have a history of smoking (41%
vs. 67%, p Z 0.09) (Table 1). There was no difference in
CTD symptoms, FVC % predicted or DLCO % predicted
between these two groups. There was a trend toward fewer
patients with definite UIP pattern in the UCTD-ILD group
(24% vs. 45%, p Z 0.13). The UCTD-ILD patients had higher
ANA titers compared to the IPF autoantibody positive
subgroup (ANA 1:320 in 50% vs. 7%, p < 0.01) (Table 2).
There were no significant differences in the frequency of
the other autoantibodies between these two groups.Circulating autoantibodies and survival
On unadjusted survival analysis, there was a trend toward
longer transplant-free survival time in patients with posi-
tive circulating autoantibodies compared to those without
positive circulating autoantibodies (HR 0.43, p Z 0.11,
Supplementary Fig. 2, Supplementary Table 2). On adjusted
analysis, the presence of positive circulating autoanti-
bodies appeared to be associated with longer transplant-
free survival time, however the statistical significance
varied depending on which statistical model was used (HR
0.22e0.47, p Z 0.03e0.17, Table 4). Additional sensitivity
analyses, including exclusion of patients with blood drawn
>6 months after initial diagnosis (n Z 4) and censoring at
lung transplant, yielded similar results (data not shown).Discussion
The type and frequency of circulating autoantibodies is not
different in patients with IPF compared to healthy, age-
similar controls. In addition, among IPF patients, there are
no differences in clinical characteristics between those
with and without circulating autoantibodies. Interestingly,
the presence of circulating autoantibodies may be associ-
ated with longer transplant-free survival time.
The significance of circulating autoantibodies in patients
with IPF has been of clinical and scientific interest for many
years. The primary concern is that these IPF autoantibody
positive patients do not have IPF, but some unrecognized
and occult CTD. Surprisingly, there are very few studies
have systematically examined the clinical relevance of this
relationship using the current definition of IPF. Fischer
et al. reported on ANA positivity in a cohort of 285 patients
with IPF and found that 34% had a positive ANA (defined as
1:40).10 They found no survival difference between IPF
patients who were ANA positive vs. negative. Vij et al.
studied an IPF cohort of 58 patients and found that 41% had
an ANA titer 1:160.8 They found other circulating auto-
antibodies in their IPF cohort, including 7% with RF and 5%
with SSA. They found no difference in survival based on ANA
titer among IPF patients with a positive ANA.
Our study expands on these earlier observations in
several important ways. First, we included a more
comprehensive and uniform assessment of circulating
autoantibodies beyond the ANA by IFA. Second, we directly
compared the phenotype of IPF patients with and without
circulating autoantibodies. Last, we compared IPF patients
to subjects from two control populations. Importantly, by
including healthy controls, we have shown that circulating
autoantibodies are no more common in patients with IPF
than in healthy, similarly aged adults.
Our finding of similar autoantibody positivity between
IPF patients and health, age-similar patients argues that
the presence of circulating autoantibodies and the pres-
ence of IPF in these patients may be unrelated; in other
words, that the presence of circulating autoantibodies in
patients with IPF may not be pathobiologically relevant.
Other investigators have reported a similar prevalence of
autoantibodies in the healthy elderly population. A study of
64 healthy individuals (32 men and 32 women, mean age 81)
reported positive RF in 14.1%, ANA in 31.3% and SSA in
Table 2 Frequency of circulating autoantibodies in IPF, healthy controls, and UCTD-ILD.
IPF
(n Z 67)
Healthy controls
(n Z 52)
p value
(healthy vs. IPF)
UCTD-ILD
(n Z 22)
p value
(UCTD vs. IPF)
ANA titer by IFA
<1:40 49 (73%) 38 (73%) 0.99 6 (27%) 0.07
1:40 and <1:320 17 (25%) 14 (27%) 0.84 5 (23%) 0.32
1:320 1 (1%) 0 (0%) 0.38 11 (50%) <0.01
ANA pattern
Speckled 17 (25%) 13 (25%) 0.85 14 (64%) 0.11
Diffuse 11 (16%) 3 (6%) 0.03 2 (9%) 0.18
Cytoplasmic 1 (1%) 1 (2%) 0.70 0 (0%) 0.24
Nucleolar 1 (1%) 0 (0%) 0.37 6 (27%) 0.10
Centromere 0 (0%) 1 (2%) 0.25 0 (0%) n/a
Rheumatoid factor >60 IU/ml 4 (6%) 0a (0%) 0.09 5 (31%) 0.35
CCP 1 (1%) 1 (2%) 0.86 2 (10%) 0.72
Centromere 0 (0%) 1 (2%) 0.25 1 (5%) 0.39
Chromatin 1 (1%) 0 (0%) 0.38 3 (14%) 0.46
dsDNA 1 (1%) 1 (2%) 0.86 1 (5%) 0.82
Jo-1 0 (0%) 0 (0%) n/a 0 (0%) n/a
RNP 4 (6%) 1 (2%) 0.28 5 (23%) 0.87
Scl-70 2 (3%) 3 (6%) 0.45 0 (0%) 0.09
Smith 0 (0%) 0 (0%) n/a 3 (14%) 0.12
Sm/RNP 0 (0%) 1 (2%) 0.25 3 (14%) 0.12
GBM 0 (0%) 0 (0%) n/a 0 (0%) n/a
Ribosomal P 0 (0%) 0 (0%) n/a 0 (0%) n/a
SSA 3 (4%) 2 (4%) 0.87 7 (32%) 0.37
SSB 0 (0%) 2 (4%) 0.11 1 (5%) 0.39
MPO 0 (0%) 0 (0%) n/a 3 (14%) 0.12
PR3 1 (1%) 0 (0%) 0.38 0 (0%) 0.24
IPF e idiopathic pulmonary fibrosis; UCTD e undifferentiated connective tissue disease; ILD e interstitial lung disease; ANA e anti-
nuclear antibody; IFA e immunofluorescence assay; CCP e anti-cyclic citrullinated peptide; dsDNA e double stranded deoxy-
ribonucleic acid; RNP e ribonucleoprotein; GBM e glomerular basement membrane; SSA e anti-Ro; SSB e anti-La; MPO e myeloper-
oxidase; PR3 e proteinase 3.
Data are presented as n (%).
a RF tested in only 48 controls.
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viduals with a mean age of 71 years found a prevalence of
14% and 18%, respectively.16 A third study of 300 healthy
subjects (mean age 79, 137 men and 163 women), found
that 17% had a positive ANA, 7.6% had a positive dsDNA, and
40% had a positive RF.17 The lack of RF positivity in our
healthy controls is interesting and may be due to the
screening process of these donors (exclusion of patients
who have hepatitis B or C, which can lead to RF positivity
that is not driven by rheumatoid arthritis18,19).
Our group and others have previously described a pop-
ulation of ILD patients with circulating autoantibodies and
signs or symptoms common to CTD who do not meet criteria
for a defined CTD.8,12,14,20 This population has been
referred to by several names including UCTD-ILD, autoim-
mune-featured (AIF) ILD, and lung-dominant CTD-ILD.8,12,14
We do not believe our population of IPF patients with
circulating autoantibodies represents this condition. The
demographics of our IPF autoantibody positive population
are different from our UCTD-ILD population. Consistent
with previous studies, our UCTD-ILD patients were younger,
mostly female, never-smokers with a predominant radio-
graphic pattern that was not UIP.12,20 Our UCTD-ILDpatients also had higher ANA titers compared to IPF auto-
antibody positive patients. Similarly, the AIF-ILD population
described by Vij et al. has a different autoantibody profile
than we found in our IPF autoantibody positive patients,
with the majority (92%) having a positive ANA and 40%
having an ANA titer 1:320.8 In fact, the autoantibody
profile in our IPF autoantibody positive group is similar to
their IPF cohort.
The survival findings of this study are provocative, but
are inconsistent based on model choice and contradict
previous reports.8,10 Additional study of this issue will be
important. Our survival findings may be due to differences
in patient populations or methods of analysis. For example,
previous studies comparing the influence of autoantibody
positivity and survival in IPF used a different ANA titer cut-
off (>1:40).10 If we analyze our data without using cut-offs
based on titer for ANA and RF, the prevalence of autoan-
tibody positivity increases but remains similar between IPF
and healthy controls (40% vs. 42%). There remain no
significant differences in baseline demographics between
autoantibody positive IPF patients compared to autoanti-
body negative IPF patients with the exception of slightly
younger age at diagnosis. Finally, all of the survival
Table 3 Comparison of autoantibody positive and auto-
antibody negative IPF.
IPF
autoantibody
positivea
(n Z 15)
IPF
autoantibody
negativea
(n Z 52)
p value
Age, years 67 (9) 70 (8) 0.15
Female gender 3 (20%) 13 (25%) 0.69
Ever smoker 10 (67%) 40 (77%) 0.42
Mean dyspnea scoreb 9.4 (6.0) 9.4 (6.2) 0.99
Joint pain or stiffness 7 (50%) 20 (41%) 0.54
Dry eyes or mouth 2 (15%) 12 (24%) 0.49
Raynaud’s 0 (0%) 4 (9%) 0.27
Reflux 4 (27%) 25 (49%) 0.13
Current prednisone
therapy
4 (31%) 14 (28%) 0.84
Current azathioprine
therapy
0 (0%) 6 (12%) 0.19
Long-term oxygen
therapy
2 (13%) 10 (20%) 0.58
Forced vital capacity,
% predicted
65 (19) 70 (17) 0.38
Diffusing capacity for
carbon monoxide,
% predicted
44 (18) 47 (18) 0.69
Definite UIP pattern
on HRCT(1)c
5 (45%) 22 (54%) 0.63
Surgical lung biopsy
performed
7 (47%) 23 (45%) 0.92
Lung transplantation 1 (7%) 5 (10%) 0.73
Number of deaths 4 (27%) 26 (50%) 0.11
Median follow-up,
days
754 (323,
1143)
1033 (269,
1316)
0.15
IPF e idiopathic pulmonary fibrosis; UIP e usual interstitial
pneumonia; HRCT e high-resolution computed tomography.
Data are presented as n (%), mean (SD), median (interquartile
range).
a Patients were categorized as autoantibody positive if they
had one or more circulating autoantibody levels above the
established reference values, except for ANA and RF. An ANA
titer of 1:320 and a RF value of 60 IU/ml were considered
positive.
b Score from Clinical-Radiographic-Physiologic (CRP) Dyspnea
Score.23
c HRCT available for re-review in 52 patients.
Table 4 Adjusted predictors of survival time in IPF.
Method 1b Method 2c
Hazard
ratio
(95% CI)
p value Hazard
ratio
(95% CI)
p value
Age 1.02
(0.97e1.08)
0.39 e
Female
gender
0.88
(0.30e2.55)
0.81 e
Ever
smoker
1.26
(0.51e3.10)
0.62 e
FVC %
predicted
e 0.97
(0.94e1.00)
0.01
DLco %
predicted
e 0.97
(0.94e1.00)
0.02
Positive
autoantibodya
0.47
(0.16e1.39)
0.17 0.23
(0.07e0.80)
0.02
IPF e idiopathic pulmonary fibrosis; CI e confidence interval;
FVC e forced vital capacity; DLco e diffusing capacity for
carbon monoxide.
a Patients were categorized as autoantibody positive if they
had one or more circulating autoantibody levels above the
established reference values, except for ANA and RF. An ANA
titer of 1:320 and a RF value of 60 IU/ml were considered
positive.
b Method 1 e This model adjusted for covariates (age, gender,
smoking history) that were identified as important confounders
in the relationship between autoantibody positivity and
survival.
c Method 2 e This model adjusted for covariates that were
found to have a p value <0.15 on unadjusted analysis.
254 J.S. Lee et al.associations (unadjusted and both adjusted methods) are
qualitatively similar but become less statistically signifi-
cant. We believe our cutoff of 1:320 is more clinically
meaningful based on the published literature on this
topic.14,21
Although the diagnosis of IPF in this cohort was made
prospectively using multidisciplinary review, we do not
know for certain if any of these patients developed
a defined CTD in the years following their diagnosis. In some
cases, autoantibody status may have been known at the
time of diagnosis and could have influenced the multidis-
ciplinary diagnosis. Also, we identified patients asautoantibody positive regardless of which autoantibody was
positive. It could be that specific autoantibodies have more
or less importance in IPF. Given the small numbers of
patients with positive autoantibodies, it was not possible to
address this issue. There were a few instances where the
BioPlex bead-based test yielded positive results for specific
autoantibodies despite the ANA by IFA demonstrating
a negative or low titer. This suggests a higher sensitivity
and/or lower specificity of the BioPlex system. When such
discrepancies occur, we generally place more clinical
weight on the ANA titer. Finally, there were autoantibodies
that were not included in the BioPlex panel including
several scleroderma-specific antibodies (Th/To, U3-RNP,
and U11/U12) and myositis antibodies.22,23
The results of this study show that circulating autoan-
tibody positivity is no more common in patients with IPF
than in healthy, age-similar adults, and that patients with
IPF and circulating autoantibodies do not represent
a distinct clinical phenotype. This suggests that the pres-
ence of circulating autoantibodies in patients with IPF may
be a reflection of aging rather than representing an occult
CTD. However, given that we do not know if these patients
developed a CTD in follow-up, these findings should be
validated in a separate cohort and future research should
focus on prospective, comprehensive evaluation of patients
with IPF to further investigate the significance of autoan-
tibodies in IPF and their relationship to survival. If vali-
dated, our findings support treating patients with IPF and
Autoantibodies in IPF 255circulating autoantibodies similarly to those without
circulating autoantibodies, including enrollment in clinical
trials of novel IPF therapies.
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